|
Jul 15
|
Sector Update: Health Care Stocks Mixed Premarket Tuesday
|
|
Jul 15
|
Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer
|
|
Jul 14
|
Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma
|
|
Jul 10
|
Iovance Biotherapeutics Appoints Marc R. Theoret, M.D. as Senior Vice President, Regulatory Strategy
|
|
Jun 29
|
Goldman Sachs Reaffirms “Buy” Rating on Iovance (IOVA) for Positive Amtagvi Data
|
|
Jun 26
|
Iovance Biotherapeutics (NasdaqGM:IOVA) Announces CFO Resignation
|
|
Jun 20
|
Gene Therapy Stocks Fall Amid More Turmoil at FDA
|
|
Jun 10
|
Iovance Biotherapeutics to Present at Upcoming Conference
|
|
May 23
|
Iovance Presents Five-Year Amtagvi Data at ASCO for Advanced Melanoma
|
|
May 22
|
Iovance Announces Five-year Results of Amtagvi® (lifileucel) in Patients with Advanced Melanoma at ASCO Annual Meeting
|
|
Apr 7
|
4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street
|
|
Apr 4
|
Iovance Biotherapeutics (NasdaqGM:IOVA) Drops 10% Over The Week In Market Correction
|
|
Mar 12
|
Down Nearly 80% From Its High, Is Iovance Biotherapeutics Stock Too Cheap to Pass Up?
|
|
Mar 4
|
Iovance Biotherapeutics (NasdaqGM:IOVA) Stock Dips 27% Despite Reaffirmed 2025 Earnings Guidance
|
|
Mar 4
|
Iovance Biotherapeutics price target lowered to $30 from $34 at Chardan
|
|
Mar 1
|
Iovance Biotherapeutics Full Year 2024 Earnings: EPS Misses Expectations
|
|
Feb 28
|
IOVA Q4 Earnings Beat, Stock Down on Looming Economic Uncertainty
|
|
Feb 28
|
Iovance Biotherapeutics Inc (IOVA) Q4 2024 Earnings Call Highlights: Strong Revenue and ...
|
|
Feb 27
|
Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Tops Revenue Estimates
|
|
Feb 27
|
Iovance Biotherapeutics: Q4 Earnings Snapshot
|